To further explore the efficacy of targeted therapies, we demonstrate that T-ALL cell lines transfected with FLT3 expression constructs were particularly sensitive to tyrosine kinase inhibitors. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.